stocks logo

MLYS

Mineralys Therapeutics Inc
$
13.880
0(0.000%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
13.880
Open
13.880
VWAP
--
Vol
3.79K
Mkt Cap
904.63M
Low
13.880
Amount
--
EV/EBITDA(TTM)
--
Total Shares
49.65M
EV
561.61M
EV/OCF(TTM)
--
P/S(TTM)
--
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone. Its product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension, CKD and OSA. Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. It has completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uncontrolled hypertension (uHTN) and resistant hypertension (rHTN). It is also investigating the benefits of lorundrostat in subjects with hypertension and CKD and in subjects with hypertension and OSA.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
--
--
-0.750
-23.47%
--
--
-0.734
-35.02%
--
--
-0.739
-11.02%
Estimates Revision
Stock Price
Go Down
down Image
-2.32%
In Past 3 Month
7 Analyst Rating
up Image
165.56% Upside
Wall Street analysts forecast MLYS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MLYS is 36.86 USD with a low forecast of 15.00 USD and a high forecast of 48.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
1 Hold
0 Sell
Strong Buy
up Image
165.56% Upside
Current: 13.880
sliders
Low
15.00
Averages
36.86
High
48.00
Jefferies
Hold
initiated
$15
2025-06-10
Reason
Jefferies initiated coverage of Mineralys Therapeutics (MLYS) with a Hold rating and $15 price target. Mineralys has a clinically derisked and novel "$1B-plus blood pressure pill" for which the firm expects the company to file for approval in 2026. Consensus assumes $1B in sales in 2033, but the firm's estimate is about 40%-50% lower due to access and competition from AstraZeneca (AZN). Upside potential can be debated if Mineralys finds a partner to accelerate the launch, but it is "hard to handicap the economics at this point and would take away a near term M/A scenario," the analyst added.
Guggenheim
Seamus Fernandez
Buy
downgrade
$52 -> $48
2025-05-14
Reason
Guggenheim analyst Seamus Fernandez lowered the firm's price target on Mineralys Therapeutics to $48 from $52 and keeps a Buy rating on the shares. The firm, which is updating its model after Q1 earnings and catching up with management, says results were "largely incremental," but highlights that Mineralys expects to have a pre-NDA meeting with the FDA in Q4 to ensure the agency and the company are aligned on expectations for the NDA package for lorundrostat.
HC Wainwright & Co.
Matthew Caufield
Strong Buy
Maintains
$30 → $42
2025-04-02
Reason
HC Wainwright & Co.
Matthew Caufield
Strong Buy
Reiterates
$30
2025-03-10
Reason
Guggenheim
Seamus Fernandez
Strong Buy
Reiterates
n/a
2025-02-24
Reason
HC Wainwright & Co.
Matthew Caufield
Strong Buy
Reiterates
$30
2025-02-13
Reason

Valuation Metrics

The current forward P/E ratio for Mineralys Therapeutics Inc (MLYS.O) is -4.73, compared to its 5-year average forward P/E of -4.05. For a more detailed relative valuation and DCF analysis to assess Mineralys Therapeutics Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.05
Current PE
-4.73
Overvalued PE
-2.83
Undervalued PE
-5.26

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.60
Current EV/EBITDA
-3.30
Overvalued EV/EBITDA
-0.15
Undervalued EV/EBITDA
-5.05

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00

Financials

Annual
Quarterly
FY2025Q1
YoY :
+25.69%
-44.45M
Operating Profit
FY2025Q1
YoY :
+33.97%
-42.21M
Net Income after Tax
FY2025Q1
YoY :
+12.86%
-0.79
EPS - Diluted
FY2025Q1
YoY :
+136.94%
-45.49M
Free Cash Flow

Trading Trends

Insider
Insiders areSelling! The selling amount has increased 232.53% over the last month.
Sold
0-3
Months
891.5K
USD
5
3-6
Months
1.4M
USD
4
6-9
Months
339.3K
USD
3
0-12
Months
352.4K
USD
2
Bought
0-3
0
0.0
USD
Months
3-6
4
37.2M
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 516.79% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
3
3.2M
Volume
Months
6-9
2
524.1K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

MLYS News & Events

Events Timeline

2025-06-30 (ET)
2025-06-30
11:23:11
Mineralys Therapeutics announces publication of Phase 3 Launch-HTN trial results
select
2025-06-17 (ET)
2025-06-17
07:03:20
Mineralys announces its Phase 2 Explore-CKD trial met primary endpoint
select
2025-05-26 (ET)
2025-05-26
08:08:00
Mineralys announces late-breaking presentation of data from Launch-HTN trial
select
Sign Up For More Events

News

4.0
07-15TipRanks
3 Best Stocks to Buy Now, 7/15/2025, According to Top Analysts
9.0
06-30Yahoo Finance
Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat
9.0
06-17Benzinga
Mineralys Therapeutics: Investigational Drug Shows Benefit In Hypertensive Patients With Chronic Kidney Disease, Stock Jumps
Sign Up For More News

FAQ

arrow icon

What is Mineralys Therapeutics Inc (MLYS) stock price today?

The current price of MLYS is 13.88 USD — it has increased 0 % in the last trading day.

arrow icon

What is Mineralys Therapeutics Inc (MLYS)'s business?

arrow icon

What is the price predicton of MLYS Stock?

arrow icon

What is Mineralys Therapeutics Inc (MLYS)'s revenue for the last quarter?

arrow icon

What is Mineralys Therapeutics Inc (MLYS)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Mineralys Therapeutics Inc (MLYS)'s fundamentals?

arrow icon

How many employees does Mineralys Therapeutics Inc (MLYS). have?

arrow icon

What is Mineralys Therapeutics Inc (MLYS) market cap?